• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Biol Pharm Bull . Improved detection sensitivity of an antigen test for SARS-CoV-2 nucleocapsid proteins with thio-NAD cycling

tetano

Editor, Senior Moderator
Biol Pharm Bull


. 2021 Jun 19.
doi: 10.1248/bpb.b21-00387. Online ahead of print.
Improved detection sensitivity of an antigen test for SARS-CoV-2 nucleocapsid proteins with thio-NAD cycling


Yuta Kyosei[SUP] 1 [/SUP], Mayuri Namba[SUP] 1 [/SUP], Sou Yamura[SUP] 1 [/SUP], Satoshi Watabe[SUP] 2 [/SUP], Teruki Yoshimura[SUP] 3 [/SUP], Tadahiro Sasaki[SUP] 4 [/SUP], Tatsuo Shioda[SUP] 4 [/SUP], Etsuro Ito[SUP] 1 2 5 [/SUP]



Affiliations

Abstract

Antigen tests for infectious diseases are inexpensive and easy-to-use, but the limit of detection (LOD) is generally higher than that of polymerase chain reaction (PCR) tests, which are considered the gold standard. In the present study, we combined a sandwich enzyme-linked immunosorbent assay (ELISA) with thionicotinamide-adenine dinucleotide (thio-NAD) cycling to improve the LOD of antigen tests for coronavirus disease 2019 (COVID-19). For recombinant nucleocapsid proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the LOD of our ELISA with thio-NAD cycling was 2.95×10[SUP]-17[/SUP] moles/assay. When UV-irradiated inactive SARS-CoV-2 was used, the minimum detectable virions corresponding to 2.6×10[SUP]4[/SUP] RNA copies/assay were obtained using our ELISA with thio-NAD cycling. The assay volume for each test was 100 μL. The minimum detectable value was smaller than that of the latest antigen test using a fluorescent immunoassay for SARS-CoV-2, indicating the validity of our detection system for COVID-19 diagnosis.

Keywords: antigen test; coronavirus disease 2019; nucleocapsid protein; severe acute respiratory syndrome coronavirus 2; thionicotinamide-adenine dinucleotide cycling; ultrasensitivity.
 
Back
Top Bottom